Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05505812 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 18, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced breast cancer.
Trial Details
NCT Number NCT05505812
Lead Sponsor The Affiliated Hospital of Qingdao University
Collaborators: Qingdao Sino-Cell Biomedicine Co., Ltd.
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov